Rokit Healthcare
Key metrics
Earnings
| Revenue, Q3 2026 | ₩6.1bn |
|---|---|
| Revenue QoQ | -25.4% |
| Revenue YoY | -11.9% |
| Operating income, Q3 2026 | -₩9.5bn |
| Operating income QoQ | +29.6% |
| Operating income YoY | Turned to loss |
Share buybacks
| Buyback decided, last 3 months | ₩0 |
|---|---|
| Buyback decided, last 3 months, % of shares | 0.0% |
| Shares acquired, last 3 months | ₩0 |
| Shares acquired, last 3 months, % of shares | 0.0% |
| Treasury shares cancelled, last 3 months | ₩0 |
| Treasury shares cancelled (number), last 3 months | 0 shares |
| Treasury shares cancelled, last 3 months, % of shares | 0.0% |
| Buyback decided, last 12 months | ₩0 |
| Buyback decided, last 12 months, % of shares | 0.0% |
| Shares acquired, last 12 months | ₩0 |
| Shares acquired, last 12 months, % of shares | 0.0% |
| Treasury shares cancelled, last 12 months | ₩0 |
| Treasury shares cancelled (number), last 12 months | 0 shares |
| Treasury shares cancelled, last 12 months, % of shares | 0.0% |
Potential dilution
| CB/BW/EB issued, last 12 months | ₩0 |
|---|---|
| Rights offering new shares, last 12 months | 903,902 shares |
| Potential new shares, last 12 months | 1,291,283 shares |
| Potential new shares, % of shares | 7.4% |
| Conversion price adjustments, last 12 months | 1 |
Supply contracts
| Supply contracts, last 12 months | ₩0 |
|---|---|
| Supply contracts vs prior-year revenue | 0.0% |
| Contracts without a KRW amount | 0 contracts without a KRW amount excluded |
Disclosure activity
| DART filings, last 3 months | 5 |
|---|---|
| DART filings, previous 3 months | 4 |
Insider transactions
| Open-market buys, last 12 months (shares) | 0 shares |
|---|---|
| Open-market buys, last 12 months (amount) | ₩0 |
| Open-market sells, last 12 months (shares) | 0 shares |
| Open-market sells, last 12 months (amount) | ₩0 |
| Net open-market buying, last 12 months (shares) | 0 shares |
| Insiders who bought, last 12 months | 0 |
Insider transactions (last 12 months)
Open-market buys: 0 shares (₩0). Open-market sells: 0 shares (₩0). Net open-market buying: 0 shares. Insiders who bought: 0.
| Trade date | Insider (role) | Type | Shares | Price | Amount | |
|---|---|---|---|---|---|---|
| Sep 11, 2026 | Lee Min-gu (Non-registered officer) | Other (Other decrease) | -28,500 shares | — | — | |
| May 15, 2026 | Gil Yun-gi (Non-registered officer) | Other (Appraisal right exercise) | +2,500 shares | ₩20,000 | ₩50m | |
| May 15, 2026 | Kim Dae-yeong (Non-registered officer) | Other (Other decrease) | 0 shares | — | — | |
| May 15, 2026 | Kim Dae-yeong (Non-registered officer) | Other (Other decrease) | 0 shares | — | — | |
| May 15, 2026 | Yoo Seok-hwan (Registered director, Controlling shareholder) | Other (Other decrease) | 0 shares | — | — | |
| May 15, 2026 | Lee Min-gu (Non-registered officer) | Other | -2,500 shares | — | — | |
| May 15, 2026 | Lee Min-gu (Non-registered officer) | Other (Appraisal right exercise) | +2,500 shares | ₩20,000 | ₩50m | |
| May 15, 2026 | Lee Sang-min (Registered director) | Other (Other decrease) | 0 shares | — | — | |
| May 15, 2026 | Lee Sang-min (Registered director) | Other (Other decrease) | 0 shares | — | — | |
| May 15, 2026 | Lee Yeong-il (Non-registered officer) | Other (Other decrease) | 0 shares | — | — | |
| Apr 21, 2026 | Gil Yun-gi (Non-registered officer) | Other | -2,500 shares | ₩20,000 | ₩50m | |
| Mar 31, 2026 | Jung Cheol-hwa (Registered director) | Other (New appointment) | +6,000 shares | — | — | |
| Mar 31, 2026 | Lee Min-gu (Non-registered officer) | Other (Stock option exercise) | +10,000 shares | — | — | Reported late |
| Mar 31, 2026 | Lee Yeong-il (Non-registered officer) | Other (Stock option exercise) | +10,000 shares | — | — | Reported late |
Annual financials
| Year | Revenue | Operating income |
|---|---|---|
| 2025 | ₩26.2bn | ₩453m |
| 2024 | ₩13.1bn | -₩5.6bn |
| 2023 | ₩12.4bn | -₩7.4bn |
Filing timeline
-
ROKIT HEALTHCARE to acquire 16.7% stake in Inopia Tech for ₩7.0bn
ROKIT HEALTHCARE Inc. filed on Nov 16, 2026 to acquire 1,400,000 shares of Inopia Tech Co., Ltd. (South Korea) for ₩7.0bn, a 16.7% equity interest, bringing its stake to 100.0%. The acquisition is expected to take place on Mar 31, 2027, and the stated purpose is strengthening business capabilities and creating synergies through acquisition of management control.
-
Rokit Healthcare adjusts conversion price to ₩48,401 after share price decline
Rokit Healthcare filed a conversion price adjustment effective Oct 19, 2026, lowering the conversion price from ₩69,144 to ₩48,401 due to a decline in share price. The number of shares issuable on conversion rises from 903,902 shares to 1,291,283 shares, an increase of 42.9% by our calculation.